Sumitomo Pharma
Introduction  is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly privately owned company funded by individuals from Tokyo and Osaka, with the land and buildings lent by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi.The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to post operating losses. In 1898 it was acquired by Osaka Seiyaku.The company is most well known for producing Philopon during WWII for the Imperial Japanese military. (Osaka Pharmaceutical).Another origin of the company began as Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical (holding 77.8% of the share as of 2006). Dainippon and Sumitomo merged on October 1, 2005, to create Dainippon Sumitomo Pharma. As a result, Sumitomo Chemical has 50.2% ownership in Dainippon Sumitomo Pharma as of March 31, 2014.On April 1, 2022, the company was renamed from Sumitomo Dainippon Pharma to Sumitomo Pharma.
Acquisitions and Consolidations Sunovion (formerly Sepracor Inc.), was acquired by then-Sumitomo Dainippon Pharma in 2010 for $2.6B.In September 2016, the Sunovion subsidiary announced it would acquire Cynapsus Therapeutics for approximately $624 million, to expand Sunovion's central nervous system drug portfolio. With the deal, Sunovion would acquire Cynapsus’ then-Phase III Parkinson's disease candidate drug APL-130277, a sublingual formulation of apomorphine.In September 2019, Sumitomo Dainippon Pharma announced a $3B upfront acquisition of five Roivant Sciences subsidiaries, including Urovant and EnzyvantIn October 2022, Sumitomo Pharma announced the acquisition of all outstanding shares in Myovant, a former Roivant Sciences subsidiary it was previously a majority owner of, valuing the company at $2.9B.In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries to form Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient needs spanning psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies.
List of mergers and acquisitions The following is an illustration of the company's major mergers and acquisitions and historical predecessors:*'''Sumitomo Pharma''' (Previously-known as '''Dainippon Sumitomo Pharma''')**Sumitomo Pharma America, Inc. (Reorganised 2023)*** Sunovion (Acq 2010)*** IBF Biotechnics (Acq 1991)*** New England Pharmaceuticals (Acq 1995)*** Oryx Pharmaceuticals (Acq 2008)*** Elevation Pharmaceuticals (Acq 2012)*** Cynapsus Therapeutics (Acq 2016)***Sumitomo Pharma America Holdings, Inc.***Sumitomo Pharma Oncology, Inc.***Sumitovant Biopharma Ltd****Myovant Sciences, Inc. (Acq 2019)****Urovant Sciences, Inc. (Acq 2019)****Enzyvant Therapeutics, Inc. (Acq 2019)****Altavant Sciences, Inc. (Acq 2019)***Spirovant Sciences, Inc. (Acq 2019)** Boston Biomedical (Acq 2012)** Tolero Pharmaceuticals (Acq 2016)
References
External links *  Sumitomo Pharma *  Sumitomo Pharma *  Official website (Archive)*  Wiki collection of bibliographic works on Sumitomo Pharma